<DOC>
	<DOCNO>NCT01278849</DOCNO>
	<brief_summary>This study design obtain pharmacokinetic data follow single-dose 20-minute i.v . administration ASA404 ( 900 , 1200 , 1800 mg/m2 ) adult cancer patient vary degree hepatic impairment . The study carry cancer volunteer patient ( utilizing control normal hepatic function ) assign four hepatic impairment group accord pre-dose ( Day-1 ) total bilirubin level . The study consist two phase , ( Core Phase ) evaluate pharmacokinetics single i.v . dose ( 900 , 1200 1800 mg/m2 ) ASA404 adult cancer patient impair hepatic function , compare control normal hepatic function . The assessment do safety tolerability single dose adult cancer patient impair hepatic function compare control normal hepatic function . The Extension Phase consist assess safety tolerability ASA404 three dose combination sponsor-approved taxane-based regimen adult cancer patient impair hepatic function compare control normal hepatic function .</brief_summary>
	<brief_title>An Open-label , Dose Escalation Study Assess Pharmacokinetics ASA404 Adult Cancer Patients With Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Vadimezan</mesh_term>
	<criteria>Patients histologicallyproven solid tumor , refractory standard chemotherapy ; Patients chemotherapy investigational agent combination docetaxel , paclitaxel + carboplatin appropriate ; Age ≥ 18 year old Creatinine clearance accord CockcroftGault formula ≥ 60 mL/min A minimum 4 week must elapse since last treatment cancer therapy ; Potassium , calcium , magnesium phosphorus value within normal range Total bilirubin ≤ 6 X ULN Patients CNS metastasis , must CT MRI brain perform rule CNS metastasis ; Patients leptomeningeal disease metastasis ; Major surgery &lt; / 4 week prior start study ; Prior exposure VDAs vascular target agent ; Right bundle branch block ( RBBB ) , complete leave bundle branch block ( LBBB ) ; Administration CYP1A2 CYP3A4/5 enzyme induce inhibit drug within 14 day prior start study drug ; Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Advanced metastatic cancer ,</keyword>
	<keyword>refractory ,</keyword>
	<keyword>core phase ,</keyword>
	<keyword>extension phase ,</keyword>
	<keyword>dose escalation ,</keyword>
	<keyword>standard chemotherapy ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>doctaxel ,</keyword>
	<keyword>paclitaxel ,</keyword>
	<keyword>carboplatin ,</keyword>
	<keyword>safety ,</keyword>
	<keyword>tolerability ,</keyword>
	<keyword>hepatic impairment</keyword>
</DOC>